{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:18:48Z","timestamp":1772173128680,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1010438","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031L0171A"],"award-info":[{"award-number":["031L0171A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031L0212E"],"award-info":[{"award-number":["031L0212E"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["161L0213"],"award-info":[{"award-number":["161L0213"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009396","name":"Universit\u00e4tsspital Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011928","name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung","doi-asserted-by":"publisher","award":["KFS-4439-02-2018"],"award-info":[{"award-number":["KFS-4439-02-2018"]}],"id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Monique Dornonville de la Cour"},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Finnish Cultural Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    The development of cancer therapies may be improved by the discovery of tumor-specific molecular dependencies. The requisite tools include genetic and chemical perturbations, each with its strengths and limitations. Chemical perturbations can be readily applied to primary cancer samples at large scale, but mechanistic understanding of hits and further pharmaceutical development is often complicated by the fact that a chemical compound has affinities to multiple proteins. To computationally infer specific molecular dependencies of individual cancers from their\n                    <jats:italic>ex vivo<\/jats:italic>\n                    drug sensitivity profiles, we developed a mathematical model that deconvolutes these data using measurements of protein-drug affinity profiles. Through integrating a drug-kinase profiling dataset and several drug response datasets, our method, DepInfeR, correctly identified known protein kinase dependencies, including the EGFR dependence of HER2+ breast cancer cell lines, the FLT3 dependence of acute myeloid leukemia (AML) with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD mutations and the differential dependencies on the B-cell receptor pathway in the two major subtypes of chronic lymphocytic leukemia (CLL). Furthermore, our method uncovered new subgroup-specific dependencies, including a previously unreported dependence of high-risk CLL on Checkpoint kinase 1 (CHEK1). The method also produced a detailed map of the kinase dependencies in a heterogeneous set of 117 CLL samples. The ability to deconvolute polypharmacological phenotypes into underlying causal molecular dependencies should increase the utility of high-throughput drug response assays for functional precision oncology.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1010438","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T13:41:36Z","timestamp":1661175696000},"page":"e1010438","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-8355","authenticated-orcid":true,"given":"Alina","family":"Batzilla","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-0746","authenticated-orcid":true,"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[]},{"given":"Jarno","family":"Kivioja","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5908","authenticated-orcid":true,"given":"Kerstin","family":"Putzker","sequence":"additional","affiliation":[]},{"given":"Joe","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2218","authenticated-orcid":true,"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"pcbi.1010438.ref001","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"JM McFarland","year":"2018","journal-title":"Nature Communications"},{"key":"pcbi.1010438.ref002","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens","volume":"568","author":"FM Behan","year":"2019","journal-title":"Nature"},{"key":"pcbi.1010438.ref003","doi-asserted-by":"crossref","first-page":"140035","DOI":"10.1038\/sdata.2014.35","article-title":"Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies","volume":"1","author":"GS Cowley","year":"2014","journal-title":"Scientific data"},{"key":"pcbi.1010438.ref004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"A Tsherniak","year":"2017","journal-title":"Cell"},{"key":"pcbi.1010438.ref005","first-page":"127","article-title":"CRISPR Gene Editing: Methods and Protocols.","volume-title":"Electroporation-Based CRISPR\/Cas9 Gene Editing Using Cas9 Protein and Chemically Modified sgRNAs.","author":"A Laustsen","year":"2019"},{"key":"pcbi.1010438.ref006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.stem.2014.10.004","article-title":"Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR\/Cas9","volume":"15","author":"PK Mandal","year":"2014","journal-title":"Cell stem cell"},{"key":"pcbi.1010438.ref007","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20199405","article-title":"Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens","volume":"16","author":"E Gon\u00e7alves","year":"2020","journal-title":"Molecular Systems Biology"},{"key":"pcbi.1010438.ref008","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nchembio1207-739","article-title":"Recognizing and exploiting differences between RNAi and small-molecule inhibitors","volume":"3","author":"WA Weiss","year":"2007","journal-title":"Nature chemical biology"},{"key":"pcbi.1010438.ref009","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1038\/ncomms15178","article-title":"Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens.","volume":"8","author":"DW Morgens","year":"2017","journal-title":"Nat Commun"},{"key":"pcbi.1010438.ref010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrd.2016.238","article-title":"Cornerstones of CRISPR\u2013Cas in drug discovery and therapy","volume":"16","author":"C Fellmann","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"key":"pcbi.1010438.ref011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-16-0178","article-title":"CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.","volume":"6","author":"DM Munoz","year":"2016","journal-title":"Cancer Discovery"},{"key":"pcbi.1010438.ref012","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"JW Tyner","year":"2018","journal-title":"Nature"},{"key":"pcbi.1010438.ref013","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.","volume":"41","author":"W Yang","year":"2012","journal-title":"Nucleic Acids Research"},{"key":"pcbi.1010438.ref014","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"S Klaeger","year":"2017","journal-title":"Science (New York, NY)."},{"key":"pcbi.1010438.ref015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","article-title":"Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia","volume":"2","author":"J Lu","year":"2021","journal-title":"Nat Cancer"},{"key":"pcbi.1010438.ref016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"S Dietrich","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"key":"pcbi.1010438.ref017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"166","author":"F Iorio","year":"2016","journal-title":"Cell"},{"key":"pcbi.1010438.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ddtec.2015.10.007","article-title":"Protein kinase profiling assays: a technology review.","volume":"18","author":"Y Wang","year":"2015","journal-title":"Drug Discov Today Technol"},{"key":"pcbi.1010438.ref019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd2541","article-title":"High-throughput kinase profiling as a platform for drug discovery.","volume":"7","author":"DM Goldstein","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"pcbi.1010438.ref020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design.","volume":"20","author":"MM Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"pcbi.1010438.ref021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"DJ Slamon","year":"1987","journal-title":"Science"},{"key":"pcbi.1010438.ref022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"S Ahn","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"pcbi.1010438.ref023","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fonc.2014.00263","article-title":"The Biology and Targeting of FLT3 in Pediatric Leukemia.","volume":"4","author":"CE Annesley","year":"2014","journal-title":"Frontiers in Oncology."},{"key":"pcbi.1010438.ref024","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.exphem.2016.04.011","article-title":"Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia","volume":"44","author":"M Griffith","year":"2016","journal-title":"Exp Hematol"},{"key":"pcbi.1010438.ref025","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","article-title":"FLT3 mutations in childhood acute lymphoblastic leukemia","volume":"103","author":"SA Armstrong","year":"2004","journal-title":"Blood"},{"key":"pcbi.1010438.ref026","doi-asserted-by":"crossref","first-page":"77163","DOI":"10.18632\/oncotarget.12848","article-title":"Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.","volume":"7","author":"MIG Raaijmakers","year":"2016","journal-title":"Oncotarget"},{"key":"pcbi.1010438.ref027","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.","volume":"9","author":"CM McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"pcbi.1010438.ref028","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/sj.onc.1203857","article-title":"The RET proto-oncogene in human cancers","volume":"19","author":"SM Jhiang","year":"2000","journal-title":"Oncogene"},{"key":"pcbi.1010438.ref029","first-page":"4746","article-title":"Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells","volume":"126","author":"S K\u00f6the","year":"2013","journal-title":"J Cell Sci"},{"key":"pcbi.1010438.ref030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"N Daver","year":"2019","journal-title":"Leukemia"},{"key":"pcbi.1010438.ref031","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/s41598-017-14033-4","article-title":"The Src family kinase LCK cooperates with oncogenic FLT3\/ITD in cellular transformation.","volume":"7","author":"A Marh\u00e4ll","year":"2017","journal-title":"Scientific reports."},{"key":"pcbi.1010438.ref032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"T Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"pcbi.1010438.ref033","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"RW Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"pcbi.1010438.ref034","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia: Presented in part at the 40th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4\u20138, 1998","volume":"94","author":"RN Damle","year":"1999","journal-title":"Blood"},{"key":"pcbi.1010438.ref035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/01621459.1971.10482356","article-title":"Objective Criteria for the Evaluation of Clustering Methods","volume":"66","author":"WM Rand","year":"1971","journal-title":"Journal of the American Statistical Association"},{"key":"pcbi.1010438.ref036","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.18632\/oncotarget.6727","article-title":"Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib","volume":"7","author":"A Guo","year":"2016","journal-title":"Oncotarget"},{"key":"pcbi.1010438.ref037","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3109\/10428191003699878","article-title":"Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma","volume":"51","author":"S Nagel","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"pcbi.1010438.ref038","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.molcel.2018.02.011","article-title":"LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia","volume":"69","author":"Y Tarumoto","year":"2018","journal-title":"Mol Cell"},{"key":"pcbi.1010438.ref039","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"H D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"pcbi.1010438.ref040","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/0008-5472.CAN-06-3545","article-title":"The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor \/progesterone receptor \/HER-2 breast carcinomas","volume":"67","author":"L Verlinden","year":"2007","journal-title":"Cancer Res"},{"key":"pcbi.1010438.ref041","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41418-019-0318-5","article-title":"CHK1 dosage in germinal center B cells controls humoral immunity.","volume":"26","author":"K Schoeler","year":"2019","journal-title":"Cell Death & Differentiation."},{"key":"pcbi.1010438.ref042","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41467-017-01850-4","article-title":"Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis","volume":"8","author":"F Schuler","year":"2017","journal-title":"Nature Communications"},{"key":"pcbi.1010438.ref043","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1016\/j.csbj.2020.11.001","article-title":"Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer","volume":"18","author":"T Wang","year":"2020","journal-title":"Computational and Structural Biotechnology Journal"},{"key":"pcbi.1010438.ref044","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells","volume":"17","author":"A H\u00f6glund","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"pcbi.1010438.ref045","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/onc.2011.358","article-title":"Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells","volume":"31","author":"PT Ferrao","year":"2012","journal-title":"Oncogene"},{"key":"pcbi.1010438.ref046","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0587.2012.07348.x","article-title":"Collinearity: a review of methods to deal with it and a simulation study evaluating their performance.","volume":"36","author":"CF Dormann","year":"2013","journal-title":"Ecography"},{"key":"pcbi.1010438.ref047","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/pgs.16.15","article-title":"Multilevel models improve precision and speed of IC50 estimates","volume":"17","author":"DJ Vis","year":"2016","journal-title":"Pharmacogenomics"},{"key":"pcbi.1010438.ref048","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest\u2014non-parametric missing value imputation for mixed-type data","volume":"28","author":"DJ Stekhoven","year":"2011","journal-title":"Bioinformatics"},{"key":"pcbi.1010438.ref049","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping.","volume":"8","author":"X Dai","year":"2017","journal-title":"Journal of Cancer"},{"key":"pcbi.1010438.ref050","first-page":"185","article-title":"Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response","volume":"9","author":"S Jernstr\u00f6m","year":"2017","journal-title":"Breast cancer (Dove Medical Press)."},{"key":"pcbi.1010438.ref051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization Paths for Generalized Linear Models via Coordinate Descent.","volume":"33","author":"J Friedman","year":"2010","journal-title":"Journal of Statistical Software."},{"key":"pcbi.1010438.ref052","article-title":"factoextra: Extract and Visualize the Results of Multivariate Data Analyses","author":"A Kassambara","year":"2019","journal-title":"R Package version 1.0.6."},{"key":"pcbi.1010438.ref053","unstructured":"Hennig C. Package \u2018fpc.\u2019 2015."},{"key":"pcbi.1010438.ref054","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1101\/gr.152132.112","article-title":"Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia","volume":"24","author":"PG Ferreira","year":"2014","journal-title":"Genome research"},{"key":"pcbi.1010438.ref055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI Love","year":"2014","journal-title":"Genome Biology"},{"key":"pcbi.1010438.ref056","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"pcbi.1010438.ref057","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection.","volume":"1","author":"A Liberzon","year":"2015","journal-title":"Cell systems"},{"key":"pcbi.1010438.ref058","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"ME Ritchie","year":"2015","journal-title":"Nucleic acids research"},{"key":"pcbi.1010438.ref059","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1073\/pnas.1211130110","article-title":"Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia","volume":"110","author":"L Vallat","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1010438","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T14:03:00Z","timestamp":1662040980000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010438"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1010438","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.11.475864","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}